一个眼睛疼痛和脑膜炎.

Same author

Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study.

ESMO real world data and digital oncology·2026

Same author

A fully 3D-printed contoured double passive scattering system for ultra-high-dose-rate irradiations.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)·2026

Same author

Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trial.

ESMO open·2025

Same author

A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Thin segmented silicon detectors for single ion tracking in carbon ion beam therapy: Performance insights.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)·2025

Same author

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].

ESMO open·2024

相关实验视频

一个眼睛疼痛和脑膜炎.

相关概念视频

Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study.

A fully 3D-printed contoured double passive scattering system for ultra-high-dose-rate irradiations.

Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trial.

A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients.

Thin segmented silicon detectors for single ion tracking in carbon ion beam therapy: Performance insights.

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].

相关实验视频

一个眼睛疼痛和脑膜炎.

相关概念视频

相关文章

Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study.

A fully 3D-printed contoured double passive scattering system for ultra-high-dose-rate irradiations.

Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trial.

A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients.

Thin segmented silicon detectors for single ion tracking in carbon ion beam therapy: Performance insights.

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].